FDA approves blood-based SimpleScreen CRC test for colorectal cancer surveillance

The FDA has approved a second blood-based colorectal cancer screening option for adults aged 45 years and older at average risk for the disease.SimpleScreen CRC (Freenome) is a noninvasive test that assesses cell-free DNA in a blood sample to detect signals associated with CRC. A positive result suggests CRC or advanced precancerous lesions and should be followed by colonoscopy, according to a